Literature DB >> 30475644

Role of TLR4-MAP4K4 signaling pathway in models of oxygen-induced retinopathy.

Wenwen Chen1,2,3,4, Juan Zhang1,2,3,4, Peijun Zhang1,2,3,4, Fangyuan Hu1,2,3,4, Tingting Jiang1,2,3,4, Junxiang Gu1,2,3,4, Qing Chang1,2,3,4.   

Abstract

Retinopathy of prematurity is a vision-threatening condition, and therapies based on antagonizing VEGF may elicit serious side effects in premature infants. Mechanisms of retinal angiogenesis, particularly the signaling pathways independent of VEGF, remain elusive. The goals of our study were to explore TLR4-mediated signaling pathways in human retinal microvascular endothelial cells (HRMECs) and to examine the effects of TLR4 antagonists in models of oxygen-induced retinopathy (OIR). Our results show that intravitreal injection of the TLR4 antagonist TAK-242 reduced areas of nonperfusion, inhibited aberrant angiogenesis, and improved vascular density in the retina of OIR mice. The effects were further potentiated by the anti-VEGF antibody ranibizumab. In cultured HRMECs, the TLR4 agonist LPS up-regulated TLR4/MAPKK kinase kinase 4 (MAP4K4) signaling, and promoted cell proliferation and migration, and reduced barrier functions of the cells. Down-regulation of MAP4K4 in HRMECs abolished the proangiogenic effects by LPS. Our data suggest that the TLR4-MAP4K4 pathway can regulate retinal neovascularization via mechanisms independent of VEGF.-Chen, W., Zhang, J., Zhang, P., Hu, F., Jiang, T., Gu, J., Chang, Q. Role of TLR4-MAP4K4 signaling pathway in models of oxygen-induced retinopathy.

Entities:  

Keywords:  VEGF; angiogenesis; retina

Mesh:

Substances:

Year:  2018        PMID: 30475644     DOI: 10.1096/fj.201801086RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  1 in total

1.  Loss of TLR4 in endothelial cells but not Müller cells protects the diabetic retina.

Authors:  Adam Seidel; Li Liu; Youde Jiang; Jena J Steinle
Journal:  Exp Eye Res       Date:  2021-03-28       Impact factor: 3.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.